Pharma BD Deal Intelligence
A $9.7B Novartis acquisition of The Medicines Company bought sole ownership of inclisiran, the twice-yearly cholesterol therapy—a bet Novartis made purely on a late-stage pipeline asset, not an existing commercial franchise.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Novartis acquired The Medicines Company for $9.7B for inclisiran cholesterol therapy.
Novartis pulled the plug on a landmark UK cholesterol outcomes trial for inclisiran, raising questions about whether real-world evidence alone can justify the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired The Medicines Company for $9.7B for inclisiran cholesterol therapy.
Leqvio (inclisiran) monotherapy — used as first-line without concomitant statin — is an expansion path supported by the VICTORION-MONO / VICTORION-1 PREVENT programs; the 1L monotherapy hypercholesterolemia market is currently statin-dominated. Statins (1L standard, different MOA): atorvastatin (Lipitor, generic), rosuvastatin (Crestor, generic), simvastatin (Zocor, generic) — near-100% generic penetration, pennies per day, and guideline-enshrined first-line. Ezetimibe (Zetia, Merck; generic) as NPC1L1 absorption inhibitor is used first-line in statin-intolerant patients. PCSK9 monoclonal antibodies (direct MOA class): evolocumab (Repatha, Amgen) and alirocumab (Praluent, Regeneron) are rarely used as true monotherapy in labels/guidelines and require payer prior authorization. ATP citrate lyase: bempedoic acid (Nexletol, Esperion) is approved for statin-intolerant primary hypercholesterolemia as monotherapy and is the most direct 1L monotherapy competitor. Pipeline: oral PCSK9 enlicitide (Merck, MK-0616) in Phase III has monotherapy arms and — if approved — is the biggest future franchise threat. Lp(a)-targeting (different target class): pelacarsen (Novartis), olpasiran (Amgen) Phase III, not LDL-C monotherapy. For a commercial lead, Leqvio monotherapy faces an existential statin generic anchor; the commercial opportunity sits in statin-intolerant high-risk patients where bempedoic acid is the incumbent.
Leqvio (inclisiran) is FDA-approved for LDL-C lowering in heterozygous familial hypercholesterolemia (HeFH) as an adjunct to maximally-tolerated statin; the HeFH competitive set mirrors broader hypercholesterolemia but is more PCSK9-intensive given genetic severity. PCSK9 monoclonal antibodies (direct MOA competitors): evolocumab (Repatha, Amgen) and alirocumab (Praluent, Regeneron) are both FDA-approved in HeFH with ~50-60% LDL-C reductions in pivotal trials (RUTHERFORD-2, ODYSSEY FH I/II). ATP citrate lyase inhibitor: bempedoic acid (Nexletol, Esperion) is approved for HeFH as oral add-on. NPC1L1 absorption inhibitor: ezetimibe (Zetia, generic) is commonly used in HeFH dual/triple oral regimens. MTP inhibitor: lomitapide (Juxtapid, Amryt/Chiesi) is approved only in homozygous FH (HoFH) — not HeFH but shares the FH franchise. ANGPTL3 antibody: evinacumab (Evkeeza, Regeneron) — HoFH approval, not HeFH. Statins (foundational, different MOA): high-intensity rosuvastatin and atorvastatin remain first-line in HeFH. Pipeline: oral PCSK9 enlicitide (Merck, MK-0616) in Phase III HeFH (CORALreef-HeFH). For a commercial lead, Leqvio's HeFH position hinges on twice-yearly dosing vs biweekly Repatha/Praluent — the chronic HeFH patient is the most compliance-sensitive segment and Leqvio's primary share opportunity.
Leqvio (inclisiran) competes in the secondary ASCVD LDL-C lowering market where statins and ezetimibe remain foundational and newer PCSK9-directed and non-statin agents compete for add-on share. PCSK9 monoclonal antibodies (direct MOA class): evolocumab (Repatha, Amgen) and alirocumab (Praluent, Regeneron/Sanofi/Regeneron full rights 2020) are FDA-approved for ASCVD LDL-C reduction with cardiovascular outcomes data (FOURIER, ODYSSEY OUTCOMES); Repatha recorded ~$2.1B 2023 global revenue (Amgen 10-K). ATP citrate lyase inhibitor: bempedoic acid (Nexletol/Nexlizet, Esperion) received expanded FDA approval in March 2024 for cardiovascular risk reduction per CLEAR Outcomes. Ezetimibe (Zetia, Merck; generic) — NPC1L1 cholesterol absorption inhibitor — is the ubiquitous oral add-on. Statins (HMG-CoA reductase inhibitors; foundational, different MOA): atorvastatin (Lipitor, generic), rosuvastatin (Crestor, generic), simvastatin (Zocor, generic). Omega-3 (icosapent ethyl, Vascepa, Amarin): used for residual triglyceride-driven ASCVD risk. Pipeline threats: oral PCSK9 inhibitors (enlicitide, Merck; MK-0616) in Phase III; lipoprotein(a) targeting pelacarsen (Novartis/Ionis) and olpasiran (Amgen) in Phase III for a separate Lp(a) indication. For a commercial lead, Leqvio's twice-yearly dosing is the key differentiation vs Repatha/Praluent — franchise threat rises sharply if oral PCSK9 (enlicitide) wins Phase III.
Closed $9.7B deal gaining inclisiran (Leqvio), twice-yearly siRNA cholesterol therapy.
First regulatory clearance for the siRNA cholesterol therapy. Regulatory step in Novartis AG's acquisition process for The Medicines Company.
Approved for ASCVD and familial hypercholesterolemia. Regulatory step in Novartis AG's acquisition process for The Medicines Company.
$754M in 2024 sales. Projected $3.4B peak by 2030. Reflects financial performance following Novartis AG's $9.7B acquisition of The Medicines Company.
$754M with 112% growth. $3.4B peak vs $2.2B breakeven supports solid returns. Assessment of Novartis AG's $9.7B acquisition of The Medicines Company and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / The Medicines Company (this deal) | 2002 | $9.7B | 67 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2002 deals · Novartis AG deals · Cardiovascular deals